Video

Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.

BenevolentAI’s Innovation Week enables our team to reflect, build and test new ideas and push the boundaries of AI in drug discovery.

Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.

Joanna Shields, CEO of BenevolentAI, a clinical-stage AI drug discovery company, presented at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January.